Valemetostat
4 clinical trials
2 abstracts
9 indications
Indication
Breast CancerIndication
Hepatocellular CarcinomaIndication
lymphomaIndication
Prostate CancerIndication
Castration-Resistant Prostate CarcinomaIndication
Clear Cell Renal Cell CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Metastatic Urothelial CarcinomaIndication
Stage IV Renal Cell Cancer AJCC v8Clinical trial
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2030-12-31
Abstract
Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with HER2 low/ultra-low/null metastatic breast cancer.Org: University of Hawaii Cancer Center, The University of Texas MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center,
Abstract
A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors.Org: National Cancer Center East, Daiichi Sankyo Ltd.,
Clinical trial
A Phase Ib/II, Dose Escalation and Dose Expansion Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma (HCC)Status: Not yet recruiting, Estimated PCD: 2027-10-31
Clinical trial
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
DS3201 With Ipilimumab in Patients With Metastatic Aggressive Variant Prostate (AVPC), Urothelial (UC), and Renal Cell (RCC) CarcinomasStatus: Recruiting, Estimated PCD: 2026-12-31